军事知识服务平台
玻璃体腔注射卡铂联合贝伐单抗治疗难治型视网膜母细胞瘤的疗效观察
Efficacy of intravitreal carboplatin plus bevacizumab in refractory retinoblastoma
摘要 目的 观察玻璃体腔注射卡铂联合贝伐单抗治疗难治型视网膜母细胞瘤的疗效.方法 前瞻性研究.选择2013年6月至2014年3月在北京大学人民医院眼科确诊的11例难治型视网膜母细胞瘤患者(11只眼),进行玻璃体腔注射卡铂联合贝伐单抗治疗,每4周1次,平均治疗4.5次.末次治疗后观察3个月,每次术中抽取前房水进行细胞学和VEGF检测,并拍摄眼底图像观察眼底情况.采用独立样本t检验进行试验组和对照组以及试验组注药前后的差异比较.结果 7例患者玻璃体腔肿瘤较注药前明显减小,4例患者肿瘤控制不佳,其中有3例为一线治疗控制后复发型患者.11例患者前房水细胞学检测未见肿瘤细胞,视网膜母细胞患者的前房水VEGF[(60.65±6.20) ng/L]较对照组[(21.98 ±6.91)ng/L]明显增高,差异有统计学意义(t=13.80,P<0.01),治疗后前房水VEGF含量较治疗前显著降低(t=2.12,P<0.05).结论 玻璃体腔注射卡铂联合贝伐单抗,对难治型视网膜母细胞瘤可能是一种相对安全、有效的治疗方法,但对复发型肿瘤疗效有限.
Abstract:
Objectives To evaluate the efficacy of intravitreal carboplatin plus bevacizumab in refractory retinoblastoma.Methods Perspective study.Eleven patients (11 eyes) with the diagnosis of refractory retinoblastoma were enrolled in Department of Ophthalmology of Peking University People's Hospital from June 2013 to March 2014.They underwent intravitreal carboplatin plus bevacizumab every 4 weeks,an average of 4.5 times of treatment.Observe for 3 months after the last treatment.Aqueous humor was taken for cytological and VEGF detection and retinal funds were taken photos for observation.Statistical analyses between experimental group and control group and before and after intravitreal injection within experimental group were performed with independent samples t test.Results Tumor in vitreous cavity reduced significantly in seven patients,however,poor control in four cases,and three of them were recurrent after first-line treatment.Cytology detection for aqueous humor showed no tumor cells in all of them.Aqueous VEGF of patients with retinoblastoma (60.65 ± 6.20) was significantly higher than the control group (21.98 ± 6.91).The difference was statistically significant (t =13.80,P <0.01).And the aqueous VEGF content decreased significantly after treatment (t =2.12,P < 0.05).Conclusion Intravitreal carboplatin plus bevacizumab,is a relatively safe,effective treatment for refractory retinoblastoma,however,ineffective for recurrent tumor.
Author: Hou Xianru Cheng Yong Zhang Qi Liang Jianhong Li Xiaoxin
作者单位: 100044,北京大学人民医院眼科中心 视觉损失与修复教育部重点实验室 视网膜脉络膜诊治研究北京市重点实验室
刊 名 中华眼科杂志 ISTICPKU
年,卷(期): 2015, 51(2)
机标分类号: R773 R285.5 R581.1
在线出版日期: 2015年3月30日
基金项目: RDC2014-24:北京大学人民医院研究与发展基金,